


Clinical Molecular Diagnostics Market to Expand at a 9.5% CAGR | 2023-2032 Forecast -Allied Market Research

The World Health Organization projects a substantial increase in the global elderly population, with an estimated 1.4 bn people aged 60 yrs and over by 2030.

WILMINGTON, DELAWARE, UNITED STATES, June 7, 2024 /EINPresswire.com/ -- The growing geriatric population serves as a pivotal driver for the robust growth of the <u>core</u> <u>clinical molecular diagnostics market</u>. Core clinical molecular diagnostics encompass vital laboratory techniques



used to analyze genetic material (DNA, RNA) and proteins at the molecular level. These techniques, including Polymerase Chain Reaction (PCR), DNA sequencing, and Next-Generation Sequencing (NGS), are integral to disease diagnosis, prognosis, and treatment selection in personalized medicine. According to the report, the global core clinical molecular diagnostics market was valued at \$4.8 billion in 2022 and is estimated to reach \$11.9 billion by 2032, exhibiting a CAGR of 9.5% from 2023 to 2032.

Core Clinical Molecular Diagnostics Market in Short:

CAGR: 9.5% Current Market Size: USD 11.9 Billion Fastest Growing Region: APAC Largest Market: North America Projection Time: 2023-2032 Base Year: 2023

Request Downloadable Sample Copy of Report: <u>https://www.alliedmarketresearch.com/request-sample/A323203</u>

What are core clinical molecular diagnostics?

Core clinical molecular diagnostics refers to the essential techniques and procedures used in medical laboratories to analyze DNA, RNA, and proteins for the purpose of diagnosing genetic disorders, infectious diseases, and other conditions at the molecular level. These diagnostics play a crucial role in personalized medicine, as they allow healthcare professionals to tailor treatments to the specific genetic makeup of individual patients.

What are the key drivers in the core clinical molecular diagnostics market report?

The major factor that fuels the growth of the core clinical molecular diagnostics market are increasing demand for precision medicine, rising prevalence of chronic diseases, and advancements in molecular diagnostics technology.

Value Propositions Related to The Report:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

Enquire Your Every Doubt Here: <u>https://www.alliedmarketresearch.com/purchase-enquiry/A323203</u>

By product type, the reagent segment accounted for the largest share in 2022, accounting for more than half of the global core clinical molecular diagnostics market revenue. This was primarily attributed to to its indispensable role in molecular diagnostics. Reagents are essential components in PCR, sequencing, and other techniques, thus driving the demand. Furthermore, rise in innovation and adoption of advanced reagents in effective diagnostic workflows drive the segment growth.

By technique, the PCR segment accounted for the largest share in 2022, accounting for half of the global core clinical molecular diagnostics market revenue. This was primarily attributed to several factors. PCR techniques are widely utilized for their versatility, sensitivity, and specificity in detecting genetic variations, infectious agents, and mutations associated with various diseases. Additionally, ongoing advancements in PCR technology, such as real-time PCR and digital PCR, further contribute to its sustained leadership in the molecular diagnostic market.

Top Leading Key Companies -

F. Hoffmann-La Roche Ltd.

Novartis, Abbott Laboratories

Becton, Dickinson and Company

Siemens Healthineers

Agilent Technologies

Hologic Inc.

Bio-Rad Laboratories Inc.

Qiagen

BioMérieux

Market: By Region Outlook

North America (U.S., Canada, Mexico)

Europe (UK, Germany, France, Spain, Italy, Rest of Europe)

Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)

LAMEA (Brazil, South Africa, Turkey, Saudi Arabia, Rest of LAMEA)

Procure Complete Report @

https://www.alliedmarketresearch.com/core-clinical-molecular-diagnostics-market/purchaseoptions

Important Questions Being Answered by This Market Report Are -

Q1. What is the total market value of core clinical molecular diagnostics market report?

Q2. What would be forecast period in the market report?

Q3. What is the market value of core clinical molecular diagnostics market in 2032?

Q4. Which is base year calculated in the core clinical molecular diagnostics market report?

Key findings of the study -

In October 2020, Cepheid (Subsidiary of Danaher Corporation) announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden in patients with Chronic Myeloid Leukemia (CML).

In May 2021, Qiagen announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received the U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa Allied Market Research + 18007925285 email us here Visit us on social media:

Facebook	
Х	
LinkedIn	

This press release can be viewed online at: https://www.einpresswire.com/article/718068336

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.